Ligand Pharmaceuticals (LGND) Profit After Tax Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
33.21% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
30.60% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
16.53% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-154.28% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Ligand Pharmaceuticals |
5.47 Bn |
4.69 Bn |
48.45 Mn |
-32.35% |
| Date | Value |
|---|
| Mar 31, 2026 |
-32.35% |
| Dec 31, 2025 |
65.84% |
| Sep 30, 2025 |
562.12% |
| Jun 30, 2025 |
95.01% |
| Mar 31, 2025 |
-40.26% |
| Dec 31, 2024 |
-79.04% |
| Sep 30, 2024 |
-33.00% |
| Jun 30, 2024 |
-54.52% |
| Mar 31, 2024 |
68.18% |
| Dec 31, 2023 |
51.05% |
| Sep 30, 2023 |
-15.31% |
| Jun 30, 2023 |
-53.02% |
| Mar 31, 2023 |
55.20% |
| Dec 31, 2022 |
-33.40% |
| Sep 30, 2022 |
26.55% |
| Jun 30, 2022 |
60.41% |
| Mar 31, 2022 |
-26.48% |
| Dec 31, 2021 |
49.67% |
| Sep 30, 2021 |
-32.91% |
| Jun 30, 2021 |
-25.11% |
